Walvax Biotech’s 13-valent Pneumococcal Conjugate Vaccine Granted Market Approval in Egypt
November 27, 2025
Source: drugdu
73
Beijing Business Today, Nov. 26 — Walvax Biotech announced that its subsidiary, Yuxi Walvax Biotech Co., Ltd., has received the "Biological Product Marketing Authorization" issued by the Egyptian Drug Authority (EDA) for its 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, signifying that the vaccine has obtained marketing approval in Egypt.
According to the announcement, the 13-valent Pneumococcal Conjugate Vaccine developed by Yuxi Walvax is primarily indicated for infants and children from 6 weeks up to 5 years of age (before their 6th birthday). It is designed to prevent infectious diseases caused by the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in the vaccine. This vaccine was initially approved for marketing in China back in 2020.
Reference: https://finance.eastmoney.com/a/202511263575601059.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
